CACNA2D3 encodes calcium channel auxiliary subunit alpha2delta-3 (alpha2delta-3), part of the alpha2delta family that regulates trafficking, surface abundance, and gating behavior of high-voltage activated calcium channels.[1][2] In neurons, alpha2delta subunits are critical determinants of presynaptic calcium entry and synaptic release fidelity, linking CACNA2D3 to circuit excitability and synaptic resilience.[2:1][3]
Within NeuroWiki’s mechanistic framework, CACNA2D3 maps to calcium signaling dysregulation, synaptic dysfunction, and ion channel dysfunction in neurodegeneration. Although CACNA2D1 is the most pharmacologically characterized alpha2delta family member in pain medicine, CACNA2D3 has distinct CNS-enriched expression and emerging disease relevance for sensory processing, excitability disorders, and network-level vulnerability.[2:2][4]
CACNA2D3 resides on chromosome 3p21.1 and produces a precursor polypeptide that is post-translationally cleaved into alpha2 and delta components, which remain linked by disulfide bonds.[1:1][2:3] The mature complex is GPI-anchored and operates as an extracellular auxiliary module for Cav channel alpha1 pore-forming subunits.[2:4]
Core mechanistic properties:
Cav channel function sets neurotransmitter release probability. By modifying channel abundance and gating, CACNA2D3 influences synaptic gain and temporal precision in neuronal communication.[2:7][3:3]
Experimental data suggest alpha2delta-3 contributes to sensory and nociceptive processing, with conserved roles across species in heat/pain-related circuit responses.[4:1]
Because calcium influx is a central second messenger for plasticity and metabolic load, alpha2delta-3 can indirectly affect pathways relevant to neurodegenerative stress, including mitochondrial burden, proteostasis pressure, and inflammatory signaling.[5][6]
Direct neurodegeneration-causative CACNA2D3 mutations are not yet established at the level of major monogenic AD/PD/ALS genes, but pathway logic and systems data support translational relevance.
Calcium dysregulation is a recurring mechanism in Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis (ALS).[5:1][6:1] Proteins controlling calcium channel trafficking, including alpha2delta family members, can shape disease-sensitive thresholds for excitotoxic and metabolic injury.
Neurodegeneration often begins with synaptic dysfunction. CACNA2D3-mediated modulation of presynaptic calcium entry places it upstream of synaptic release failures and plasticity breakdown that precede overt cell death.[3:4][5:2]
Activity-dependent calcium signaling contributes to neuron-glia crosstalk and inflammatory tone. Perturbations in channel-support proteins may therefore have secondary effects on inflammatory amplification loops in chronic neurodegeneration.[5:3]
Population and sequencing studies have associated CACNA2D3 variation with epilepsy and neurodevelopmental phenotypes, highlighting its role in excitation-control biology relevant to broader circuit diseases.[7][8]
Rare-variant and copy-number studies have reported CACNA2D3 involvement in subsets of neurodevelopmental disorders, consistent with altered synaptic development/signaling.[8:1][9]
Experimental models identified alpha2delta-3 as an evolutionarily conserved regulator of heat nociception and central pain pathway processing, reinforcing its importance in neuronal signal integration.[4:2]
Clinically used gabapentinoids primarily target alpha2delta-1/2 complexes; nevertheless, alpha2delta family pharmacology illustrates that auxiliary channel subunits are druggable nodes.[10] Understanding CACNA2D3-specific biology may enable more CNS-selective next-generation modulators.
Because calcium channels serve ubiquitous physiology, subtype selectivity and dose-window control are essential to avoid cognitive, psychiatric, sensory, or cardiovascular off-target effects.[2:8][10:1]
NCBI Gene. CACNA2D3 calcium voltage-gated channel auxiliary subunit alpha2delta 3. ↩︎ ↩︎
Dolphin AC. Calcium channel auxiliary alpha2delta and beta subunits: trafficking and one step beyond. Nature Reviews Neuroscience. 2012. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Eroglu C, Allen NJ, Susman MW, et al. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell. 2009. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Neely GG, Hess A, Costigan M, et al. A genome-wide Drosophila screen for heat nociception identifies alpha2delta3 as an evolutionarily conserved pain gene. Cell. 2010. ↩︎ ↩︎ ↩︎
Berridge MJ. Calcium hypothesis of Alzheimer's disease. Pflugers Archiv. 2016. ↩︎ ↩︎ ↩︎ ↩︎
Surmeier DJ, Halliday GM, Simuni T. Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease. Experimental Neurology. 2017. ↩︎ ↩︎
Butler KM, da Silva C, Alexander JJ, et al. De novo and inherited KCNA2 variants in developmental and epileptic encephalopathy. Annals of Neurology. 2016. ↩︎
Iossifov I, O'Roak BJ, Sanders SJ, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014. ↩︎ ↩︎
Satterstrom FK, Kosmicki JA, Wang J, et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell. 2020. ↩︎
Fink K, Meder W, Dooley DJ, Gothert M. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in human neocortex. Naunyn-Schmiedeberg's Archives of Pharmacology. 2004. ↩︎ ↩︎